Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 520 | 138 | 376 |
| Samples | 296 | 98 | 195 |
| Peptides | 233 | 53 | 185 |
Function
CLNK · Cytokine dependent hematopoietic cell linker
MIST is a member of the SLP76 family of adaptors (see LCP2, MIM 601603; BLNK, MIM 604515). MIST plays a role in the regulation of immunoreceptor signaling, including PLC-gamma (PLCG1; MIM 172420)-mediated B cell antigen receptor (BCR) signaling and FC-epsilon R1 (see FCER1A, MIM 147140)-mediated mast cell degranulation (Cao et al., 1999 [PubMed 10562326]; Goitsuka et al., 2000, 2001 [PubMed 10744659] [PubMed 11463797]).[supplied by OMIM, Mar 2008].
Isoforms & Proteins
3 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
Gene Properties
Recurrent Mutations
All 218 amino-acid changes on canonical ENST00000226951 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in CLNK · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in CLNK – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| Chronic Myelogenous Leukemia | 2/25 8% | 0/0 0% |
| T-Cell Non-Hodgkins Lymphoma | 1/26 4% | 0/0 0% |
| Glioblastoma | 3/98 3% | 0/0 0% |
| Non-Small Cell Lung Carcinoma | 20/304 7% | 20/1390 1% |
| Endometrial Carcinoma | 2/42 5% | 13/612 2% |
| Acute Myeloid Leukemia | 2/90 2% | 0/0 0% |
| Melanoma | 12/210 6% | 27/1899 1% |
| Oral Cavity Carcinoma | 1/54 2% | 0/0 0% |
| Cervical Carcinoma | 2/35 6% | 4/422 1% |
| Other Sarcomas | 2/69 3% | 7/699 1% |
| Colorectal Carcinoma | 12/143 8% | 27/3239 1% |
| Other Solid Cancers | 2/94 2% | 14/1515 1% |
| Neuroendocrine Tumour | 6/154 4% | 1/577 0% |
| Osteosarcoma | 2/45 4% | 0/166 0% |
| Bladder Carcinoma | 3/58 5% | 6/956 1% |
| Squamous Cell Lung Carcinoma | 0/57 0% | 7/810 1% |
| Gastric Carcinoma | 4/74 5% | 10/1809 1% |
| Ovarian Carcinoma | 4/109 4% | 4/998 0% |
| Small Cell Lung Carcinoma | 0/9 0% | 5/752 1% |
| Ewings Sarcoma | 2/63 3% | 0/262 0% |
| Glioma | 2/52 4% | 9/2127 0% |
| Rhabdomyosarcoma | 0/33 0% | 1/171 1% |
| Hepatocellular Carcinoma | 3/46 7% | 7/2210 0% |
| Biliary Tract Carcinoma | 0/54 0% | 4/950 0% |
| Esophageal Carcinoma | 0/23 0% | 3/769 0% |
| Esophageal Squamous Cell Carcinoma | 4/51 8% | 5/2550 0% |
| Pancreatic Carcinoma | 0/89 0% | 5/1611 0% |
| Plasma Cell Myeloma | 0/44 0% | 1/305 0% |
| Breast Carcinoma | 1/144 1% | 8/3264 0% |
| Non-Cancerous | 1/104 1% | 1/830 0% |
Mutation Distribution
Where CLNK is mutated · all tissues, split by cell line vs tissue
How many mutations in CLNK were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 43 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 520 mutations in CLNK
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|